Additional file 1 of A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Additional file 1: Supplementary Table 1. Definitions used in the study. Supplementary Table 2. Details of eligibility criteria. Supplementary Table 3. Patient reported outcome tool: mMIDAS. Supplementary Table 4. Change from baseline in MMD by visit, observed,mixed model repeated measures (full analysis set). Supplementary Table 5. Patientincidence rates of treatment-emergent SAEs in the study by primary SOC (Safety analysis set)

Additional file 1 of Unveiling the therapeutic potential of Dl-3-n-butylphthalide in NTG-induced migraine mouse: activating the Nrf2 pathway to alleviate oxidative stress and neuroinflammation

Supplementary Material 1